Cadrenal Therapeutics closed at $1.06 on Nov 4, down 6.19%, 92.1% below its 52-week closing high. Volume of 43.2K shares was 0.21× its 20-day average (below normal).
Split-adjusted performance: +7.1% over one month, -82.8% over six months, -92.1% over one year.
Short interest was 281.4K shares at the Oct 15 settlement, up 165.6% from the prior report (9.2% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CVKDCadrenal Therapeutics | $1.06 | −6.19% | −82.8% | — | — | — | $3.8M | |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
| TRAWTraws Pharma | $0.2686 | −11.06% | −84.2% | −100.0% | — | — | $4.1M | Compare |
| KALAKALA BIO | $0.1781 | +2.95% | −96.9% | — | — | — | $3.4M | Compare |
| DRMADermata Therapeutics | $0.8548 | +0.72% | −32.7% | — | — | — | $4.2M | Compare |
| SXTP60 Degrees Pharmaceuticals | $0.9563 | −5.32% | −42.4% | −32.5% | −1152.6% | — | $3.4M | Compare |
| APUSApimeds Pharmaceuticals US | $2.92 | −1.68% | −85.0% | — | — | — | $4.4M | Compare |
| JUNSJupiter Neurosciences | $2.46 | +1.23% | −91.0% | — | −9380.9% | — | $3.2M | Compare |
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
